Progression of immunotherapy in gastric cancer / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 225-232, 2016.
Artículo
en Chino
| WPRIM
| ID: wpr-341552
ABSTRACT
Gastric cancer is a malignant disease with high incidence and mortality. The therapeutic methods for advanced gastric cancer, including chemotherapy and targeted therapy are very limited. Immunotherapy is a new method for cancer treatment. The immune checkpoint inhibitors developed for cancer treatment mainly target the CTLA-4 and PD-1/PD-L pathways. There have already been several inhibitors approved for the treatment of melanoma and non-small cell lung cancer by the FDA, including Ipilimumab (fully human antibody against CTLA-4), Pembrolizumab (fully human antibody against PD-1) and Nivolumab (fully human antibody against PD-1). There are also many on-going clinical trials investigating the value of immune checkpoint inhibitors in treating various malignancies, including advanced gastric cancer. In KEYNOTE-012 trial, for advanced gastric and esophagogastric junction cancer anti-PD-1 therapy seemed to be safe and effective for advanced gastric cancer with PD-L1 positivity. Moreover, studies of adoptive cell therapy and tumor vaccine in gastric cancer are underway. Here the latest developments in immunotherapy for gastric cancer will be illustrated.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Gástricas
/
Terapéutica
/
Progresión de la Enfermedad
/
Usos Terapéuticos
/
Anticuerpos Monoclonales Humanizados
/
Antígeno B7-H1
/
Antígeno CTLA-4
/
Receptor de Muerte Celular Programada 1
/
Ipilimumab
/
Inmunoterapia
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Gastrointestinal Surgery
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS